Fast Track Designation facilitates development and expedites regulatory review of therapies addressing serious conditions with significant ...
Fast Track Designation facilitates development and expedites regulatory review of therapies addressing serious conditions with significant unmet medical need - - QRX003 lotion (4%) currently being ...
NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company developing transformative therapies for the treatment of cancer and rare ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果